Cite
Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myeloma.
MLA
Campbell, Lauren, et al. “Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma.” British Journal of Haematology, vol. 185, no. 4, May 2019, pp. 775–78. EBSCOhost, https://doi.org/10.1111/bjh.15615.
APA
Campbell, L., Panitsas, F., Basu, S., Anyanwu, F., Lee, S., Ferry, B., & Ramasamy, K. (2019). Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myeloma. British Journal of Haematology, 185(4), 775–778. https://doi.org/10.1111/bjh.15615
Chicago
Campbell, Lauren, Fotios Panitsas, Supratik Basu, Francis Anyanwu, Sophie Lee, Berne Ferry, and Karthik Ramasamy. 2019. “Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma.” British Journal of Haematology 185 (4): 775–78. doi:10.1111/bjh.15615.